# Radiofrequency Ablation for Recurrent Pleural Mesothelioma

## TL;DR

Radiofrequency ablation shows promise as a safe and effective treatment for recurrent pleural mesothelioma, with high local tumor control and survival rates.

## Contribution

This study is the first to report on the use of RFA for recurrent pleural mesothelioma, demonstrating its feasibility and clinical benefits.

## Key findings

- RFA achieved 92% local tumor control in treated lesions.
- Overall survival rates were 100% at 3 years and 60% at 5 years.
- Only 4.3% of cases experienced major or minor complications.

## Abstract

Pleural mesothelioma is a rare but highly aggressive malignancy that often relapses, posing major therapeutic challenges. We investigated radiofrequency ablation (RFA) as a minimally invasive option for patients with recurrent disease. We retrospectively reviewed the data of 14 patients treated with RFA to assess its safety and clinical impact. The procedure was feasible in all sessions, with only one major complication (4.3%) and one minor event (4.3%). Local tumor control was achieved in 92% of treated lesions, and the estimated overall survival at 3 and 5 years reached 100% and 60%, respectively. These findings indicate that RFA may be a valuable addition to current treatment strategies for recurrent pleural mesothelioma. Prospective studies are warranted to confirm our findings and clarify the integration of RFA into multimodal care.

Background/Objectives: Pleural mesothelioma (PM) frequently recurs despite multimodal therapy. Here, we aimed to retrospectively evaluate the safety and potential clinical benefit of radiofrequency ablation (RFA) for recurrent PM. Methods: Fourteen consecutive patients underwent CT-guided RFA between July 2019 and June 2025. The cohort comprised 13 men and 1 woman, with a median age of 69 (range, 54–77) years. All patients had previously received systemic therapy, and 12 had undergone surgery. Seven patients (50%) presented with multiple lesions, and 25 tumors (median diameter 1.8 cm; range, 0.5–7.0 cm) were treated in 23 sessions. Outcomes assessed were local tumor control, complications, and survival. Local progression and overall survival were estimated using Kaplan–Meier analysis. Adverse events were classified according to the Society of Interventional Radiology guidelines. Results: Technical success was achieved in all sessions. Two tumors showed local recurrence, corresponding to 1- and 2-year local progression rates of 10.6%. Seven patients showed distant metastases, most of whom subsequently received systemic therapy. Three patients died, two from disease progression and one from treatment-related gastrointestinal perforation during therapy for an unrelated cancer. The overall survival rates were 100%, 100%, and 60% at 1, 3, and 5 years, respectively. Major and minor complications occurred in one case each (4.3%): a refractory skin ulcer and retroperitoneal hematoma, respectively. Conclusions: RFA was technically feasible and generally well tolerated and helped achieve encouraging local control and survival in patients with recurrent PM, warranting further evaluation of RFA as a complementary approach in multimodal treatment strategies.